{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:38:55Z","timestamp":1793392735383,"version":"4.5.0"},"reference-count":167,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.autrev.2017.07.004","type":"journal-article","created":{"date-parts":[[2017,7,8]],"date-time":"2017-07-08T18:01:06Z","timestamp":1499536866000},"page":"925-936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Spasticity in multiple sclerosis: Contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions"],"prefix":"10.1016","volume":"16","author":[{"given":"Robert","family":"Patejdl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe K.","family":"Zettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0005","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/WCO.0b013e3283534a8a","article-title":"Autoinflammatory grey matter lesions in humans: cortical encephalitis, clinical disorders, experimental models","volume":"25","author":"Junker","year":"2012","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.autrev.2011.05.008","article-title":"Immune-mediated CNS diseases: a review on nosological classification and clinical features","volume":"11","author":"Zettl","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0015","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2015.11.005","article-title":"Multiple sclerosis and fatigue: a review on the contribution of inflammation and immune-mediated neurodegeneration","volume":"15","author":"Patejdl","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2015.04.012","article-title":"Promoting sympathovagal balance in multiple sclerosis; pharmacological, non-pharmacological, and surgical strategies","volume":"15","author":"Sternberg","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.004_bb0025","doi-asserted-by":"crossref","first-page":"354906","DOI":"10.1155\/2014\/354906","article-title":"Pathophysiology of spasticity: implications for neurorehabilitation","volume":"2014","author":"Trompetto","year":"2014","journal-title":"Biomed Res Int"},{"issue":"4","key":"10.1016\/j.autrev.2017.07.004_bb0030","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/1352458510364992","article-title":"Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis","volume":"16","author":"Tallantyre","year":"2010","journal-title":"Mult Scler"},{"issue":"Pt 8","key":"10.1016\/j.autrev.2017.07.004_bb0035","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/brain\/121.8.1469","article-title":"Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study","volume":"121","author":"de Stefano","year":"1998","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0165-5728(99)00081-8","article-title":"Pathogenesis of tissue injury in MS lesions","volume":"98","author":"Trapp","year":"1999","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2017.07.004_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jneumeth.2014.01.014","article-title":"Characterizations of reflex and nonreflex changes in spastic multiple sclerosis","volume":"231","author":"Zhang","year":"2014","journal-title":"J Neurosci Methods"},{"issue":"8","key":"10.1016\/j.autrev.2017.07.004_bb0050","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1474-4422(07)70193-X","article-title":"Spastic movement disorder: impaired reflex function and altered muscle mechanics","volume":"6","author":"Dietz","year":"2007","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0055","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1748-1716.2006.01652.x","article-title":"The spinal pathophysiology of spasticity\u2014from a basic science point of view","volume":"189","author":"Nielsen","year":"2007","journal-title":"Acta Physiol (Oxf)"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0060","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/197140091202500305","article-title":"Neuroimaging assessment of spasticity developed after acquired brain injuries and multiple sclerosis","volume":"25","author":"Bertoni","year":"2012","journal-title":"Neuroradiol J"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0065","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/brain\/104.3.431","article-title":"Electrophysiological studies of gait in spasticity and rigidity. Evidence that altered mechanical properties of muscle contribute to hypertonia","volume":"104","author":"Dietz","year":"1981","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.autrev.2017.07.004_bb0070","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00019052-199612000-00010","article-title":"Reflex hyperexcitability and muscle contracture in relation to spastic hypertonia","volume":"9","author":"O'Dwyer","year":"1996","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2017.07.004_bb0075","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/mus.20059","article-title":"Structural and functional changes in spastic skeletal muscle","volume":"29","author":"Lieber","year":"2004","journal-title":"Muscle Nerve"},{"issue":"Pt 1","key":"10.1016\/j.autrev.2017.07.004_bb0080","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1113\/jphysiol.2006.116749","article-title":"Fibre type-specific increase in passive muscle tension in spinal cord-injured subjects with spasticity","volume":"577","author":"Olsson","year":"2006","journal-title":"J Physiol (Lond)"},{"issue":"8","key":"10.1016\/j.autrev.2017.07.004_bb0085","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/jor.22068","article-title":"Passive mechanical properties of rat abdominal wall muscles suggest an important role of the extracellular connective tissue matrix","volume":"30","author":"Brown","year":"2012","journal-title":"J Orthop Res"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0090","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/0888439002250449","article-title":"Spasticity in multiple sclerosis","volume":"17","author":"Barnes","year":"2003","journal-title":"Neurorehabil Neural Repair"},{"issue":"12","key":"10.1016\/j.autrev.2017.07.004_bb0095","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1177\/1352458514566416","article-title":"The high cost of spasticity in multiple sclerosis to individuals and society","volume":"21","author":"Stevenson","year":"2015","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0100","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/ane.12202","article-title":"Spasticity in patients with multiple sclerosis\u2014clinical characteristics, treatment and quality of life","volume":"129","author":"Flachenecker","year":"2014","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0105","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/1531-8257(199903)14:2<331::AID-MDS1020>3.0.CO;2-H","article-title":"Anatomic correlates of painful tonic spasms in multiple sclerosis","volume":"14","author":"Spissu","year":"1999","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.autrev.2017.07.004_bb0110","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1191\/1352458504ms1085oa","article-title":"Prevalence and treatment of spasticity reported by multiple sclerosis patients","volume":"10","author":"Rizzo","year":"2004","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.autrev.2017.07.004_bb0115","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40271-016-0173-0","article-title":"A cross-sectional study of the impact of spasticity on daily activities in multiple sclerosis","volume":"9","author":"Bethoux","year":"2016","journal-title":"Patient"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2017.07.004_bb0120","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0035-3787(12)70047-4","article-title":"Spasticity and everyday life in multiple sclerosis","volume":"168","author":"Donz\u00e9","year":"2012","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.autrev.2017.07.004_bb0125","series-title":"Multiple Sklerose: Kausalorientierte, symptomatische und rehabilitative Therapie","article-title":"Diagnostik, Klassifikation und Therapie der Spastik bei Multipler Sklerose","author":"Benecke","year":"2001"},{"issue":"7","key":"10.1016\/j.autrev.2017.07.004_bb0130","first-page":"113","article-title":"Multiple sclerosis registry in Germany: results of the extension phase 2005\/2006","volume":"105","author":"Flachenecker","year":"2008","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"10.1016\/j.autrev.2017.07.004_bb0135","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/ane.12612","article-title":"Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry","volume":"135","author":"Skierlo","year":"2017","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0140","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0166-2236(00)02088-9","article-title":"Cytokine-induced sickness behaviour: mechanisms and implications","volume":"25","author":"Konsman","year":"2002","journal-title":"Trends Neurosci"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0145","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0149-7634(88)80004-6","article-title":"Biological basis of the behavior of sick animals","volume":"12","author":"Hart","year":"1988","journal-title":"Neurosci Biobehav Rev"},{"issue":"6 Pt 2","key":"10.1016\/j.autrev.2017.07.004_bb0150","first-page":"R1712","article-title":"Involvement of cyclooxygenase-2 in LPS-induced fever and regulation of its mRNA by LPS in the rat brain","volume":"272","author":"Cao","year":"1997","journal-title":"Am J Physiol"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1385\/NMM:3:1:15","article-title":"Neuronal overexpression of COX-2 results in dominant production of PGE2 and altered fever response","volume":"3","author":"Vidensky","year":"2003","journal-title":"Neuromolecular Med"},{"issue":"5","key":"10.1016\/j.autrev.2017.07.004_bb0160","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.smim.2014.01.011","article-title":"Getting nervous about immunity","volume":"26","author":"Kelley","year":"2014","journal-title":"Semin Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0165","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000065186","article-title":"Alteration of locus coeruleus neuronal activity by interleukin-1 and the involvement of endogenous corticotropin-releasing hormone","volume":"10","author":"Borsody","year":"2002","journal-title":"Neuroimmunomodulation"},{"issue":"1\u20133","key":"10.1016\/j.autrev.2017.07.004_bb0170","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.regpep.2005.01.004","article-title":"Interleukin-1beta depolarizes magnocellular neurons in the paraventricular nucleus of the hypothalamus through prostaglandin-mediated activation of a non-selective cationic conductance","volume":"129","author":"Ferri","year":"2005","journal-title":"Regul Pept"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0175","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1046\/j.1365-2826.2003.00870.x","article-title":"Interleukin-1 beta depolarizes paraventricular nucleus parvocellular neurones","volume":"15","author":"Ferri","year":"2003","journal-title":"J Neuroendocrinol"},{"issue":"4","key":"10.1016\/j.autrev.2017.07.004_bb0180","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0361-9230(96)00196-7","article-title":"Effects of IL-1 beta on neuronal activities in the dorsal motor nucleus of the vagus in rat brain slices","volume":"41","author":"Mo","year":"1996","journal-title":"Brain Res Bull"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12311-014-0613-0","article-title":"IL-1beta dependent cerebellar synaptopathy in a mouse mode of multiple sclerosis","volume":"14","author":"Mandolesi","year":"2015","journal-title":"Cerebellum"},{"issue":"5","key":"10.1016\/j.autrev.2017.07.004_bb0190","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s12576-012-0215-x","article-title":"Interleukin-6 inhibits L-type calcium channel activity of cultured cerebellar granule neurons","volume":"62","author":"Ma","year":"2012","journal-title":"J Physiol Sci"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0195","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1017\/neu.2013.49","article-title":"Interleukin-6 inhibits voltage-gated sodium channel activity of cultured rat spinal cord neurons","volume":"26","author":"Li","year":"2014","journal-title":"Acta Neuropsychiatr"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0200","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ceca.2015.06.006","article-title":"Interleukin-6 reduces NMDAR-mediated cytosolic Ca(2)(+) overload and neuronal death via JAK\/CaN signaling","volume":"58","author":"Ma","year":"2015","journal-title":"Cell Calcium"},{"issue":"9","key":"10.1016\/j.autrev.2017.07.004_bb0205","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3109\/02699052.2013.794970","article-title":"Interleukin-6 prevents NMDA-induced neuronal Ca2+ overload via suppression of IP3 receptors","volume":"27","author":"Liu","year":"2013","journal-title":"Brain Inj"},{"issue":"44","key":"10.1016\/j.autrev.2017.07.004_bb0210","doi-asserted-by":"crossref","first-page":"11391","DOI":"10.1523\/JNEUROSCI.3708-08.2008","article-title":"Cell death after spinal cord injury is exacerbated by rapid TNF alpha-induced trafficking of GluR2-lacking AMPARs to the plasma membrane","volume":"28","author":"Ferguson","year":"2008","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0215","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1096\/fj.11-192716","article-title":"Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons","volume":"26","author":"He","year":"2012","journal-title":"FASEB J"},{"issue":"5","key":"10.1016\/j.autrev.2017.07.004_bb0220","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1046\/j.1471-4159.1998.70051876.x","article-title":"The transcription factor NF-kappaB mediates increases in calcium currents and decreases in NMDA- and AMPA\/kainate-induced currents induced by tumor necrosis factor-alpha in hippocampal neurons","volume":"70","author":"Furukawa","year":"1998","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0225","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.expneurol.2004.12.026","article-title":"Tumor necrosis-factor-alpha (TNF-alpha) induces rapid insertion of Ca2+-permeable alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA)\/kainate (Ca-A\/K) channels in a subset of hippocampal pyramidal neurons","volume":"193","author":"Ogoshi","year":"2005","journal-title":"Exp Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0230","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1471-4159.2010.06634.x","article-title":"Tumour necrosis factor alpha induces rapid reduction in AMPA receptor-mediated calcium entry in motor neurones by increasing cell surface expression of the GluR2 subunit: relevance to neurodegeneration","volume":"113","author":"Rainey-Smith","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.autrev.2017.07.004_bb0235","doi-asserted-by":"crossref","first-page":"861231","DOI":"10.1155\/2014\/861231","article-title":"Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity","volume":"2014","author":"Olmos","year":"2014","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.autrev.2017.07.004_bb0240","doi-asserted-by":"crossref","first-page":"124942","DOI":"10.1155\/2015\/124942","article-title":"Modulation of voltage-gated sodium channels by activation of tumor necrosis factor receptor-1 and receptor-2 in small DRG neurons of rats","volume":"2015","author":"Leo","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"7","key":"10.1016\/j.autrev.2017.07.004_bb0245","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/89490","article-title":"CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity","volume":"4","author":"Bezzi","year":"2001","journal-title":"Nat Neurosci"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0250","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000026433","article-title":"Cytokine effects on glutamate uptake by human astrocytes","volume":"7","author":"Hu","year":"2000","journal-title":"Neuroimmunomodulation"},{"issue":"8","key":"10.1016\/j.autrev.2017.07.004_bb0255","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/archneur.60.8.1082","article-title":"Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid","volume":"60","author":"Sarchielli","year":"2003","journal-title":"Arch Neurol"},{"issue":"Pt A","key":"10.1016\/j.autrev.2017.07.004_bb0260","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuropharm.2014.10.027","article-title":"Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability","volume":"96","author":"Vezzani","year":"2015","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.autrev.2017.07.004_bb0265","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/1352458510364196","article-title":"Cerebrospinal fluid ATP metabolites in multiple sclerosis","volume":"16","author":"Lazzarino","year":"2010","journal-title":"Mult Scler"},{"issue":"19","key":"10.1016\/j.autrev.2017.07.004_bb0270","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1523\/JNEUROSCI.5265-09.2010","article-title":"Demyelination increases axonal stationary mitochondrial size and the speed of axonal mitochondrial transport","volume":"30","author":"Kiryu-Seo","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.autrev.2017.07.004_bb0275","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40478-015-0261-8","article-title":"Differential expression of glucose-metabolizing enzymes in multiple sclerosis lesions","volume":"3","author":"Nijland","year":"2015","journal-title":"Acta Neuropathol Commun"},{"issue":"Pt 5","key":"10.1016\/j.autrev.2017.07.004_bb0280","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/brain\/awp046","article-title":"Mitochondrial changes within axons in multiple sclerosis","volume":"132","author":"Mahad","year":"2009","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0285","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/WCO.0b013e3283533a25","article-title":"Mitochondrial changes within axons in multiple sclerosis: an update","volume":"25","author":"Campbell","year":"2012","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2017.07.004_bb0290","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nm.2324","article-title":"A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"17","author":"Nikic","year":"2011","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0295","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1152\/jn.00775.2010","article-title":"Adrenergic receptors modulate motoneuron excitability, sensory synaptic transmission and muscle spasms after chronic spinal cord injury","volume":"105","author":"Rank","year":"2011","journal-title":"J Neurophysiol"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0300","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1191\/135248506ms1250oa","article-title":"The efficacy of multidisciplinary rehabilitation in stable multiple sclerosis patients","volume":"12","author":"Storr","year":"2006","journal-title":"Mult Scler"},{"issue":"11","key":"10.1016\/j.autrev.2017.07.004_bb0305","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1177\/1352458516643600","article-title":"Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper","volume":"22","author":"Otero-Romero","year":"2016","journal-title":"Mult Scler"},{"issue":"Suppl. 6","key":"10.1016\/j.autrev.2017.07.004_bb0310","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00415-008-6021-y","article-title":"Muscle rupture caused by exacerbated spasticity in a patient with multiple sclerosis","volume":"255","author":"Patejdl","year":"2008","journal-title":"J Neurol"},{"issue":"6","key":"10.1016\/j.autrev.2017.07.004_bb0315","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2340\/16501977-0811","article-title":"Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up","volume":"43","author":"Rekand","year":"2011","journal-title":"J Rehabil Med"},{"issue":"4","key":"10.1016\/j.autrev.2017.07.004_bb0320","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/NRE-161329","article-title":"Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: long term follow-up","volume":"38","author":"Stampacchia","year":"2016","journal-title":"NeuroRehabilitation"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0325","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1742-4801.2005.00075.x","article-title":"Pressure sores with associated spasticity: a clinical challenge","volume":"2","author":"Atiyeh","year":"2005","journal-title":"Int Wound J"},{"issue":"7","key":"10.1016\/j.autrev.2017.07.004_bb0330","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.disamonth.2013.03.013","article-title":"The diagnosis and management of lower urinary tract symptoms in multiple sclerosis patients","volume":"59","author":"Sand","year":"2013","journal-title":"Dis Mon"},{"issue":"6","key":"10.1016\/j.autrev.2017.07.004_bb0335","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40291-014-0114-3","article-title":"Effects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients","volume":"18","author":"Rommer","year":"2014","journal-title":"Mol Diagn Ther"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0340","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/sc.2014.155","article-title":"Effects of intrathecal triamincinolone-acetonide treatment in MS patients with therapy-resistant spasticity","volume":"53","author":"Kamin","year":"2015","journal-title":"Spinal Cord"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0345","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/cns.12474","article-title":"Long-term effects of repeated cycles of intrathecal triamcinolone acetonide on spasticity in MS patients","volume":"22","author":"Rommer","year":"2016","journal-title":"CNS Neurosci Ther"},{"issue":"29","key":"10.1016\/j.autrev.2017.07.004_bb0350","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.2174\/138161212802502251","article-title":"Management of spasticity in progressive multiple sclerosis: efficacy of repeated intrathecal triamcinolone acetonide administration","volume":"18","author":"Abu-Mugheisib","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0355","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10571-014-0117-y","article-title":"Effect of methylprednisolone on mammalian neuronal networks in vitro","volume":"35","author":"Wittstock","year":"2015","journal-title":"Cell Mol Neurobiol"},{"issue":"13","key":"10.1016\/j.autrev.2017.07.004_bb0360","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/WNR.0b013e32834a282a","article-title":"High-dose glucocorticoids induce decreases calcium in hypothalamus neurons via plasma membrane Ca(2+) pumps","volume":"22","author":"Chen","year":"2011","journal-title":"Neuroreport"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0365","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0306-4522(96)00624-0","article-title":"Corticosteroid effects on sodium and calcium currents in acutely dissociated rat CA1 hippocampal neurons","volume":"78","author":"Werkman","year":"1997","journal-title":"Neuroscience"},{"issue":"11","key":"10.1016\/j.autrev.2017.07.004_bb0370","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/cdd.2013.108","article-title":"Potent and multiple regulatory actions of microglial glucocorticoid receptors during CNS inflammation","volume":"20","author":"Carrillo-de Sauvage","year":"2013","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0375","first-page":"44","article-title":"Interferon-beta inhibits Th1 responses at the dendritic cell level. Relevance to multiple sclerosis","volume":"99","author":"Bartholome","year":"1999","journal-title":"Acta Neurol Belg"},{"issue":"7","key":"10.1016\/j.autrev.2017.07.004_bb0380","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.4049\/jimmunol.1000271","article-title":"B cells as a therapeutic target for IFN-beta in relapsing-remitting multiple sclerosis","volume":"186","author":"Ramgolam","year":"2011","journal-title":"J Immunol"},{"issue":"29","key":"10.1016\/j.autrev.2017.07.004_bb0385","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.2174\/138161212802502215","article-title":"An inventory of short term and long term changes in gene expression under interferon beta treatment of relapsing remitting MS patients","volume":"18","author":"Paap","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0390","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/tpj.2010.77","article-title":"Network analysis of transcriptional regulation in response to intramuscular interferon-beta-1a multiple sclerosis treatment","volume":"12","author":"Hecker","year":"2012","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0395","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12035-013-8463-1","article-title":"Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood","volume":"48","author":"Hecker","year":"2013","journal-title":"Mol Neurobiol"},{"issue":"8","key":"10.1016\/j.autrev.2017.07.004_bb0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070626","article-title":"Multiple sclerosis: modulation of toll-like receptor (TLR) expression by interferon-beta includes upregulation of TLR7 in plasmacytoid dendritic cells","volume":"8","author":"Derkow","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.autrev.2017.07.004_bb0405","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1172\/JCI33342","article-title":"The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice","volume":"118","author":"Guo","year":"2008","journal-title":"J Clin Invest"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2017.07.004_bb0410","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-510X(02)00047-3","article-title":"Comparison of glatiramer acetate (Copaxone\u00ae) and interferon \u03b2-1b (Betaferon\u00ae) in multiple sclerosis patients: an open-label 2-year follow-up","volume":"197","author":"Flechter","year":"2002","journal-title":"J Neurol Sci"},{"issue":"8","key":"10.1016\/j.autrev.2017.07.004_bb0415","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/WNL.53.8.1622","article-title":"Multiple sclerosis: side effects of interferon beta therapy and their management","volume":"53","author":"Walther","year":"1999","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0420","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/jnnp.2003.018598","article-title":"The effect of interferon beta-1a on spasticity in primary progressive multiple sclerosis","volume":"75","author":"Leary","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1016\/j.autrev.2017.07.004_bb0425","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1212\/WNL.53.8.1892-a","article-title":"Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b","volume":"53","author":"Frese","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.autrev.2017.07.004_bb0430","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1212\/WNL.51.6.1720","article-title":"Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b","volume":"51","author":"Bramanti","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2017.07.004_bb0435","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neuropharm.2015.06.009","article-title":"Interferon-beta1a modulates glutamate neurotransmission in the CNS through CaMKII and GluN2A-containing NMDA receptors","volume":"100","author":"Di Filippo","year":"2016","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0440","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1152\/jn.01224.2003","article-title":"Neuromodulation by a cytokine: interferon-beta differentially augments neocortical neuronal activity and excitability","volume":"93","author":"Hadjilambreva","year":"2005","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.autrev.2017.07.004_bb0445","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12974-014-0185-4","article-title":"Protein kinase C activation mediates interferon-beta-induced neuronal excitability changes in neocortical pyramidal neurons","volume":"11","author":"Reetz","year":"2014","journal-title":"J Neuroinflammation"},{"issue":"8","key":"10.1016\/j.autrev.2017.07.004_bb0450","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/hipo.22129","article-title":"Toll-like receptor 3 activation modulates hippocampal network excitability, via glial production of interferon-beta","volume":"23","author":"Costello","year":"2013","journal-title":"Hippocampus"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2017.07.004_bb0455","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2011.11.010","article-title":"Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-b to glatiramer acetate: the Escala study","volume":"315","author":"Meca-Lallana","year":"2012","journal-title":"J Neurol Sci"},{"issue":"5","key":"10.1016\/j.autrev.2017.07.004_bb0460","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.autrev.2012.09.005","article-title":"The mechanism of action of glatiramer acetate in multiple sclerosis and beyond","volume":"12","author":"Aharoni","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0465","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13561-015-0066-2","article-title":"Cost analysis of glatiramer acetate versus interferon-beta for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study","volume":"5","author":"La Sanchez-de Rosa","year":"2015","journal-title":"Health Econ Rev"},{"issue":"12","key":"10.1016\/j.autrev.2017.07.004_bb0470","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/jnr.23440","article-title":"Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate","volume":"92","author":"Moore","year":"2014","journal-title":"J Neurosci Res"},{"issue":"11","key":"10.1016\/j.autrev.2017.07.004_bb0475","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00702-009-0272-3","article-title":"Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate","volume":"116","author":"Arnon","year":"2009","journal-title":"J Neural Transm"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0480","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11481-013-9436-x","article-title":"Glatiramer acetate protects against inflammatory synaptopathy in experimental autoimmune encephalomyelitis","volume":"8","author":"Gentile","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"issue":"6","key":"10.1016\/j.autrev.2017.07.004_bb0485","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.clinthera.2010.06.005","article-title":"Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study","volume":"32","author":"Meca-Lallana","year":"2010","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0490","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1590\/S0004-282X2013000300002","article-title":"Natalizumab adverse events are rare in patients with multiple sclerosis","volume":"71","author":"Fragoso","year":"2013","journal-title":"Arq Neuropsiquiatr"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0495","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/ene.12618","article-title":"Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM","volume":"22","author":"Voloshyna","year":"2015","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0500","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1468-1331.2010.03112.x","article-title":"Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis","volume":"18","author":"Belachew","year":"2011","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0505","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053297","article-title":"Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis","volume":"8","author":"Cadavid","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0510","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1124\/jpet.111.190132","article-title":"Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway","volume":"341","author":"Scannevin","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0515","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin Neuropharmacol"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2017.07.004_bb0520","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jns.2008.06.031","article-title":"Central nervous system-directed effects of FTY720 (fingolimod)","volume":"274","author":"Miron","year":"2008","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0525","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ana.24217","article-title":"Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide","volume":"76","author":"Colombo","year":"2014","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.autrev.2017.07.004_bb0530","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1476-5381.2011.01579.x","article-title":"Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis","volume":"165","author":"Rossi","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0535","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.clinph.2014.05.031","article-title":"Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis","volume":"126","author":"Landi","year":"2015","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.autrev.2017.07.004_bb0540","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.expneurol.2014.04.003","article-title":"Neuroprotective dimethyl fumarate synergizes with immunomodulatory interferon beta to provide enhanced axon protection in autoimmune neuroinflammation","volume":"257","author":"Reick","year":"2014","journal-title":"Exp Neurol"},{"issue":"5","key":"10.1016\/j.autrev.2017.07.004_bb0545","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/jnc.13456","article-title":"In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity","volume":"136","author":"Luchtman","year":"2016","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.autrev.2017.07.004_bb0550","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1139\/cjpp-2016-0346","article-title":"Cannabinoid signaling in health and disease","volume":"95","author":"Lu","year":"2017","journal-title":"Can J Physiol Pharmacol"},{"issue":"6","key":"10.1016\/j.autrev.2017.07.004_bb0555","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.autrev.2016.02.008","article-title":"Cannabinoids and autoimmune diseases: a systematic review","volume":"15","author":"Katchan","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0560","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/1756285615612659","article-title":"Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis","volume":"9","author":"Zettl","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0565","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000112901","article-title":"The perceived effects of smoked cannabis on patients with multiple sclerosis","volume":"38","author":"Consroe","year":"1997","journal-title":"Eur Neurol"},{"issue":"9","key":"10.1016\/j.autrev.2017.07.004_bb0570","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","article-title":"A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(\u00ae)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis","volume":"18","author":"Novotna","year":"2011","journal-title":"Eur J Neurol"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0575","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11481-014-9575-8","article-title":"Neuroprotection in experimental autoimmune encephalomyelitis and progressive multiple sclerosis by cannabis-based cannabinoids","volume":"10","author":"Pryce","year":"2015","journal-title":"J Neuroimmune Pharmacol"},{"issue":"5","key":"10.1016\/j.autrev.2017.07.004_bb0580","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10787-014-0214-z","article-title":"Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters","volume":"22","author":"Sexton","year":"2014","journal-title":"Inflammopharmacology"},{"issue":"6773","key":"10.1016\/j.autrev.2017.07.004_bb0585","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/35003583","article-title":"Cannabinoids control spasticity and tremor in a multiple sclerosis model","volume":"404","author":"Baker","year":"2000","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.autrev.2017.07.004_bb0590","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.neuropharm.2012.01.030","article-title":"Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects","volume":"62","author":"de Lago","year":"2012","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.autrev.2017.07.004_bb0595","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.bjp.0707003","article-title":"Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors","volume":"150","author":"Pryce","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2017.07.004_bb0600","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.neuropharm.2014.01.007","article-title":"Pre- and postsynaptic type-1 cannabinoid receptors control the alterations of glutamate transmission in experimental autoimmune encephalomyelitis","volume":"79","author":"Musella","year":"2014","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.autrev.2017.07.004_bb0605","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S1474-4422(13)70159-5","article-title":"Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial","volume":"12","author":"Zajicek","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2017.07.004_bb0610","series-title":"GABAb receptor pharmacology: a tribute to Norman Bowery","first-page":"123","article-title":"GABAB receptor coupling to G-proteins and ion channels","author":"Padgett","year":"2010"},{"key":"10.1016\/j.autrev.2017.07.004_bb0615","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neuroscience.2014.04.037","article-title":"GABA transport and neuroinflammation are coupled in multiple sclerosis: regulation of the GABA transporter-2 by ganaxolone","volume":"273","author":"Paul","year":"2014","journal-title":"Neuroscience"},{"issue":"11","key":"10.1016\/j.autrev.2017.07.004_bb0620","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.autrev.2015.07.011","article-title":"Immunological GABAergic interactions and therapeutic applications in autoimmune diseases","volume":"14","author":"Prud'homme","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2017.07.004_bb0625","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/apha.12467","article-title":"GABAergic signalling in the immune system","volume":"213","author":"Barragan","year":"2015","journal-title":"Acta Physiol (Oxf)"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0630","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0165-5728(98)00264-1","article-title":"GABA(A) receptors mediate inhibition of T cell responses","volume":"96","author":"Tian","year":"1999","journal-title":"J Neuroimmunol"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2017.07.004_bb0635","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.neuropharm.2010.11.007","article-title":"An intrinsic GABAergic system in human lymphocytes","volume":"60","author":"Dionisio","year":"2011","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.autrev.2017.07.004_bb0640","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.173.8.5298","article-title":"Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model","volume":"173","author":"Tian","year":"2004","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2017.07.004_bb0645","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1073\/pnas.0915139107","article-title":"Inhibitory role for GABA in autoimmune inflammation","volume":"107","author":"Bhat","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.autrev.2017.07.004_bb0650","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.molimm.2010.08.005","article-title":"Increased GABA(A) channel subunits expression in CD8(+) but not in CD4(+) T cells in BB rats developing diabetes compared to their congenic littermates","volume":"48","author":"Mendu","year":"2011","journal-title":"Mol Immunol"},{"issue":"8","key":"10.1016\/j.autrev.2017.07.004_bb0655","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042959","article-title":"Different subtypes of GABA-A receptors are expressed in human, mouse and rat T lymphocytes","volume":"7","author":"Mendu","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.autrev.2017.07.004_bb0660","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003051","article-title":"GABAergic signaling is linked to a hypermigratory phenotype in dendritic cells infected by Toxoplasma gondii","volume":"8","author":"Fuks","year":"2012","journal-title":"PLoS Pathog"},{"issue":"9","key":"10.1016\/j.autrev.2017.07.004_bb0665","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.molimm.2005.07.025","article-title":"Human peripheral blood mononuclear cells express GABAA receptor subunits","volume":"43","author":"Alam","year":"2006","journal-title":"Mol Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2017.07.004_bb0670","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/TP.0b013e31829c24be","article-title":"GABA protects human islet cells against the deleterious effects of immunosuppressive drugs and exerts immunoinhibitory effects alone","volume":"96","author":"Prud'homme","year":"2013","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0675","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017152","article-title":"Anaesthetic impairment of immune function is mediated via GABA(A) receptors","volume":"6","author":"Wheeler","year":"2011","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.autrev.2017.07.004_bb0680","doi-asserted-by":"crossref","first-page":"7242","DOI":"10.4049\/jimmunol.174.11.7242","article-title":"Gamma-amino butyric acid type B receptors stimulate neutrophil chemotaxis during ischemia-reperfusion","volume":"174","author":"Rane","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2017.07.004_bb0685","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3389\/fncel.2015.00284","article-title":"Modulation of TLR3\/TLR4 inflammatory signaling by the GABAB receptor agonist baclofen in glia and immune cells: relevance to therapeutic effects in multiple sclerosis","volume":"9","author":"Crowley","year":"2015","journal-title":"Front Cell Neurosci"},{"issue":"12","key":"10.1016\/j.autrev.2017.07.004_bb0690","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.4049\/jimmunol.181.12.8226","article-title":"Gamma-aminobutyric acid transporter 1 negatively regulates T cell-mediated immune responses and ameliorates autoimmune inflammation in the CNS","volume":"181","author":"Wang","year":"2008","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2017.07.004_bb0695","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.4049\/jimmunol.0900767","article-title":"Gamma-aminobutyric acid transporter 1 negatively regulates T cell activation and survival through protein kinase C-dependent signaling pathways","volume":"183","author":"Wang","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2017.07.004_bb0700","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/B978-0-444-52001-2.00008-X","article-title":"The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment","volume":"122","author":"Robinson","year":"2014","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0705","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S1568-9972(02)00102-7","article-title":"MHC class II peptide flanking residues of exogenous antigens influence recognition by autoreactive T cells","volume":"2","author":"Conant","year":"2003","journal-title":"Autoimmun Rev"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2017.07.004_bb0710","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jneuroim.2008.08.017","article-title":"GABA, a natural immunomodulator of T lymphocytes","volume":"205","author":"Bjurst\u00f6m","year":"2008","journal-title":"J Neuroimmunol"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2017.07.004_bb0715","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneuroim.2012.11.001","article-title":"Systemic treatment with the inhibitory neurotransmitter \u03b3-aminobutyric acid aggravates experimental autoimmune encephalomyelitis by affecting proinflammatory immune responses","volume":"255","author":"Carmans","year":"2013","journal-title":"J Neuroimmunol"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0720","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1254\/jphs.FP0050520","article-title":"Involvement of supraspinal imidazoline receptors and descending monoaminergic pathways in tizanidine-induced inhibition of rat spinal reflexes","volume":"99","author":"Kino","year":"2005","journal-title":"J Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0725","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0165-1781(00)00216-X","article-title":"The effects of noradrenaline and alpha-2 adrenoceptor agents on the production of monocytic products","volume":"96","author":"Maes","year":"2000","journal-title":"Psychiatry Res"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.004_bb0730","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1128\/IAI.71.1.22-29.2003","article-title":"Resistance of macrophages to Mycobacterium avium is induced by alpha2-adrenergic stimulation","volume":"71","author":"Weatherby","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.autrev.2017.07.004_bb0735","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-007513","article-title":"Stretching the limbs? Tonic spasms in multiple sclerosis","volume":"2012","author":"Andrade","year":"2012","journal-title":"BMJ Case Rep"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0740","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/brain\/98.2.189","article-title":"Paroxysmal attacks in multiple sclerosis","volume":"98","author":"Ostermann","year":"1975","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0745","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/1352458514564486","article-title":"A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult Scler"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2017.07.004_bb0750","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11064-015-1809-5","article-title":"Neuroprotection as a potential therapeutic perspective in neurodegenerative diseases: focus on antiepileptic drugs","volume":"41","author":"Caccamo","year":"2016","journal-title":"Neurochem Res"},{"issue":"8","key":"10.1016\/j.autrev.2017.07.004_bb0755","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070019","article-title":"Biomarker report from the phase II lamotrigine trial in secondary progressive MS \u2014 neurofilament as a surrogate of disease progression","volume":"8","author":"Gnanapavan","year":"2013","journal-title":"PLoS One"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2017.07.004_bb0760","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1528-1167.2011.03035.x","article-title":"Antiepileptic drugs and the immune system","volume":"52","author":"Beghi","year":"2011","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.autrev.2017.07.004_bb0765","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1254\/jphs.FP0040537","article-title":"GABAB receptors do not mediate the inhibitory actions of gabapentin on the spinal reflex in rats","volume":"96","author":"Shimizu","year":"2004","journal-title":"J Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0770","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/jcb.20064","article-title":"Ryanodine receptor signaling is required for anti-CD3-induced T cell proliferation, interleukin-2 synthesis, and interleukin-2 receptor signaling","volume":"92","author":"Conrad","year":"2004","journal-title":"J Cell Biochem"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0775","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0361-9230(98)00005-7","article-title":"Calcium channel blockers and dantrolene differentially regulate the production of interleukin-12 and interferon-gamma in endotoxemic mice","volume":"46","author":"Nemeth","year":"1998","journal-title":"Brain Res Bull"},{"issue":"6","key":"10.1016\/j.autrev.2017.07.004_bb0780","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/emmm.201202124","article-title":"A TSPO ligand is protective in a mouse model of multiple sclerosis","volume":"5","author":"Daugherty","year":"2013","journal-title":"EMBO Mol Med"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0785","first-page":"186","article-title":"Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis","volume":"72","author":"Brar","year":"1991","journal-title":"Arch Phys Med Rehabil"},{"issue":"6","key":"10.1016\/j.autrev.2017.07.004_bb0790","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.pmrj.2015.10.005","article-title":"Intrathecal versus oral baclofen: a matched cohort study of spasticity, pain, sleep, fatigue, and quality of life","volume":"8","author":"McCormick","year":"2016","journal-title":"PM R"},{"issue":"4","key":"10.1016\/j.autrev.2017.07.004_bb0795","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1034\/j.1600-0404.2000.101004244x.\/","article-title":"Effect of baclofen on gait in spastic MS patients","volume":"101","author":"Orsnes","year":"2000","journal-title":"Acta Neurol Scand"},{"issue":"11","key":"10.1016\/j.autrev.2017.07.004_bb0800","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/jnnp.57.11.1355","article-title":"Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud)","volume":"57","author":"Emre","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.autrev.2017.07.004_bb0805","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/YIC.0000000000000126","article-title":"The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity","volume":"31","author":"Marinelli","year":"2016","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.autrev.2017.07.004_bb0810","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jns.2016.09.054","article-title":"Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray","volume":"370","author":"Squintani","year":"2016","journal-title":"J Neurol Sci"},{"issue":"4","key":"10.1016\/j.autrev.2017.07.004_bb0815","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/jnnp.2004.054635","article-title":"Depression in multiple sclerosis: a review","volume":"76","author":"Siegert","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.autrev.2017.07.004_bb0820","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1177\/1352458511417835","article-title":"Multiple sclerosis and depression","volume":"17","author":"Feinstein","year":"2011","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.004_bb0825","first-page":"135","article-title":"Symptomatic fatigue in multiple sclerosis","volume":"65","author":"Freal","year":"1984","journal-title":"Arch Phys Med Rehabil"},{"issue":"2","key":"10.1016\/j.autrev.2017.07.004_bb0830","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00887825","article-title":"Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction","volume":"242","author":"Chia","year":"1995","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.autrev.2017.07.004_bb0835","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1212\/WNL.38.12.1830","article-title":"Pain syndromes in multiple sclerosis","volume":"38","author":"Moulin","year":"1988","journal-title":"Neurology"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217301726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217301726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T10:55:26Z","timestamp":1692874526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997217301726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":167,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1568997217301726"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2017.07.004","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spasticity in multiple sclerosis: Contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2017.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}